•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, presented preclinical data for its lead ecDNA-directed therapy (ecDTx) BBI-940 at the American Association for Cancer Research (AACR) Annual Meeting 2026. The company said it has identified a novel kinesin target essential to ecDNA segregation and inheritance in cancer cells, while being non-essential in healthy cells.
Boundless Bio reported that genetic and pharmacologic degradation of kinesin led to ecDNA mis-segregation, ecDNA depletion, and reduced viability of ecDNA-positive cancer cells. In a panel of tumor cell lines, selective kinesin degradation showed sensitivity across multiple tumor types, with 32% sensitivity in breast cancer cell lines, including those positive for ecDNA and FGFR1 gain.
The company said the kinesin-degradation subgroup was further validated in vivo, including monotherapy tumor regressions in an ecDNA-positive TNBC-LAR model. It also reported significant antitumor activity as monotherapy and in combination in an ecDNA-positive/FGFR1-positive ER-positive breast cancer model.
Boundless Bio said BBI-940 is a potentially first-in-class, oral, and selective kinesin degrader currently being evaluated in the Phase 1 KOMODO-1 trial (NCT07408089). The trial is enrolling patients with advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR).
Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio, said the company discovered and validated a kinesin target critical for ecDNA segregation during cell division. He added that selective degradation of the target produced potent antitumor activity in validated breast cancer models, particularly those with ecDNA, and that the genetic, in vitro, in vivo, and toxicity profile supported initiation of the KOMODO-1 trial.
Boundless Bio described BBI-940 as an oral, selective kinesin degrader designed to exploit what it characterizes as the heightened dependence of ecDNA-positive tumors on mitotic machinery. The therapy is intended to degrade kinesin to induce mitotic catastrophe and cell death, targeting a kinesin protein essential for ecDNA segregation and inheritance in cancer cells while being non-essential in healthy cells.
Boundless Bio is headquartered in San Diego, California. The company said ecDNA is a root cause of oncogene amplification observed in 14% to 17% of cancer patients. It is developing BBI-940 as an ecDNA-directed therapeutic candidate (ecDTx) for oncogene amplified cancers.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
